NASDAQ | ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions.
The fund generally is expected to consist of more than 15 companies but not more than 100 companies.
The fund is non-diversified.
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| LLY | Eli Lilly and Company | Healthcare | Drug Manufacturers - General | 6.33% |
| VRTX | Vertex Pharmaceuticals Inc | Healthcare | Biotechnology | 5.78% |
| AMGN | Amgen Inc | Healthcare | Drug Manufacturers - General | 5.12% |
| ALNY | Alnylam Pharmaceuticals Inc | Healthcare | Biotechnology | 4.73% |
| NOVO-B | Novo Nordisk A/S | Healthcare | Biotechnology | 3.94% |
| CRNX | Crinetics Pharmaceuticals Inc | Healthcare | Biotechnology | 3.83% |
| 0QIU | Novo Nordisk A/S Class B | 3.70% | ||
| BBIO | BridgeBio Pharma Inc | Healthcare | Biotechnology | 3.63% |
| 4519 | Chugai Pharmaceutical Co. Ltd. | Healthcare | Drug Manufacturers - General | 3.56% |
| CYTK | Cytokinetics Inc | Healthcare | Biotechnology | 3.50% |
| BSX | Boston Scientific Corp | Healthcare | Medical Devices | 3.28% |
| AZN | AstraZeneca PLC | Healthcare | Drug Manufacturers - General | 3.18% |
| MDT | Medtronic PLC | Healthcare | Medical Devices | 3.02% |
| ASND | Ascendis Pharma AS | Healthcare | Biotechnology | 3.00% |
| DXCM | DexCom Inc | Healthcare | Medical Devices | 2.79% |
| MASI | Masimo Corporation | Healthcare | Medical Devices | 2.55% |
| MIRM | Mirum Pharmaceuticals Inc | Healthcare | Biotechnology | 2.47% |
| REGN | Regeneron Pharmaceuticals Inc | Healthcare | Biotechnology | 2.46% |
| IONS | Ionis Pharmaceuticals Inc | Healthcare | Biotechnology | 2.33% |
| MREO | Mereo BioPharma Group PLC ADR | Healthcare | Biotechnology | 2.31% |